foxo4-dri human trials (Proxofim) 10mg*10 vials - Nexus peptides FOXO4-DRI UK | Senolytic Peptide

It is not intended forhuman or veterinary use, consumption, administration, or clinical application

FOXO4-DRI enhances tissue rejuvenation By clearing out senescent cells, FOXO4-DRI can cause a significant increase in the regeneration of tissues and may restore their functionality, making it a promising agent for reversing cellular aging effects (4)

Blocking FOXO4, which inhibits the activation of P53, causes senescent cells to undergo apoptosis by P53 activation, without affecting healthy cells around them, and has anti-aging effects which may have potential applications in the treatment of numerous age-related diseases, as well as an adjunct to treatment for certain forms of cancer

There is also evidence that long COVID may trigger latent herpesvirusesparticularly Epstein-Barr virus (EBV) and cytomegalovirus (CMV)in some patients

Should I use a new syringe for every injection